Glimepiride Accord

Glimepiride Accord is a prescription oral medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent. While the specific dosage strength and dosage form are not disclosed, the product is marketed within the European Union for the management of blood glucose in adults with type 2 diabetes mellitus. It works by stimulating insulin release from pancreatic beta cells and helps improve glycemic control.

Glimepiride Accord is indicated for the oral treatment of type 2 diabetes mellitus in adults, typically as part of a comprehensive diabetes management plan.

- Improves fasting and post‑prandial blood glucose levels when combined with diet and exercise. - May be used as monotherapy in patients who have not achieved glycemic targets with lifestyle changes alone. - Can be added to other oral antidiabetic agents such as metformin when combination therapy is required. - May assist in reducing HbA1c levels over several weeks of consistent use. - Is prescribed when clinicians aim to stimulate endogenous insulin secretion in patients with residual pancreatic beta‑cell function.

The safety profile of Glimepiride Accord includes a range of adverse effects that vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia) - Nausea or abdominal discomfort - Headache - Dizziness or light‑headedness - Weight gain - Fatigue

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as rash, itching, or swelling - Hepatic dysfunction indicated by elevated liver enzymes - Blood disorders like leukopenia or thrombocytopenia - Cardiovascular events such as arrhythmia - Pancreatitis symptoms (upper abdominal pain)

Before initiating Glimepiride Accord, healthcare providers should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function, as impairment may alter drug clearance. - Verify that the patient retains sufficient pancreatic beta‑cell activity to respond to sulfonylureas. - Use caution in elderly patients due to increased susceptibility to hypoglycemia. - Review any history of cardiovascular disease, especially if concomitant with other hypoglycemic agents. - Avoid use during pregnancy or breastfeeding unless the benefit outweighs potential risks. - Monitor blood glucose regularly after dose adjustments. - Educate patients on recognizing and managing hypoglycemia symptoms.

Glimepiride Accord can interact with several medicines, affecting its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, as they may reduce glucose control. - Antidepressants such as SSRIs, which have been reported to affect blood sugar regulation. - Antifungal agents like itraconazole, requiring close glucose monitoring.